Pub. Date : 2014
PMID : 24505265
8 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 2 | Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 3 | In KRAS mutant patients who had used oxaliplatin-based regimens (N = 131), the OS was significantly longer than that in KRAS mutant patients who had never-used oxaliplatin-based regimens (N = 38). | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 4 | The OS was 28.8 months [95% confidence interval (CI): 23.2-34.4] in KRAS mutant patients who had used oxaliplatin-based regimens versus 17.8 months [95% CI: 6.5-29.1] in KRAS mutant patients who had never-used oxaliplatin-based regimens (P = 0.026). | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 5 | The OS was 28.8 months [95% confidence interval (CI): 23.2-34.4] in KRAS mutant patients who had used oxaliplatin-based regimens versus 17.8 months [95% CI: 6.5-29.1] in KRAS mutant patients who had never-used oxaliplatin-based regimens (P = 0.026). | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 6 | In multivariate analyses, patients who had used oxaliplatin-based regimens remains an independent prognostic factor for longer OS in KRAS mutant mCRC patients. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 7 | In conclusion, oxaliplatin-based regimens are more beneficial in KRAS mutant than in KRAS wild-type mCRC patients. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |
| 8 | In conclusion, oxaliplatin-based regimens are more beneficial in KRAS mutant than in KRAS wild-type mCRC patients. | Oxaliplatin | KRAS proto-oncogene, GTPase | Homo sapiens |